Search company, investor...

Founded Year



Acq - Fin - II | Alive



About ArisGlobal

ArisGlobal is a company focused on providing cloud-based solutions for the life sciences sector. The company offers an end-to-end drug development platform that automates core functions of the drug development lifecycle, including safety, clinical, regulatory, and medical affairs. ArisGlobal primarily serves the life sciences industry, including pharmaceutical and biotech companies, contract research organizations, and regulatory agencies. It was founded in 1987 and is based in Miami, Florida.

Headquarters Location

3119 Ponce De Leon Blvd

Miami, Florida, 33134,

United States

+1 609-360-4042


ESPs containing ArisGlobal

The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.

Healthcare & Life Sciences / Drug R&D Tech

The decentralized clinical trials market offers various solutions that allow for remote participation in clinical trials, including telemedicine, mobile health applications, and wearable devices. By removing the need for frequent visits to clinical trial sites, decentralized trials can improve patient enrollment, retention, and overall trial efficiency. Additionally, decentralized trials can enhan…

ArisGlobal named as Leader among 15 other companies, including Medable, Huma, and Curebase.


Expert Collections containing ArisGlobal

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

ArisGlobal is included in 1 Expert Collection, including Digital Health.


Digital Health

10,585 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Latest ArisGlobal News

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety

Nov 9, 2023

New Study Confirms Power of Real-World Data in Proactive Signal Detection, Improving Patient Safety Challenging a discipline that has barely evolved in 70 years, ArisGlobal’s patent-pending Proactive Signal Detection technology demonstrates 40% greater accuracy than established detection methods Boston, Massachusetts, USA – November 8, 2023 – ArisGlobal , creator of the LifeSphere® technology platform and a market leader in global patient treatment solutions, has announced striking new study results confirming the power of Proactive Safety Signal Detection in improving patient safety. Specifically, the findings support the technology’s ability to distill precise, meaningful drug-event insights directly and efficiently from real-world data, boosting drug safety – while potentially also supporting new indications. A foundational and comparative study of ArisGlobal’s LifeSphere® Proactive Signal Detection technology, drew on 12 years of Individual Case Safety Reports (ICSRs) (over 6 million, from Vigibase) and EMR and claims records (18,000, c/o Patient Lives). The findings revealed: a 39% improvement in signal optimization. The foundational study tested whether it was possible to create a signal strength that will be directly correlated to the likelihood that a drug-event combination (DEC) would become a validated signal, and how well an adverse event (AE) could be detected in real-world data. The comparative study then looked at the capacity to reduce false positives, compared to traditional methods (the precision rate); and to what extent the Proactive Signal Detection method successfully captured true signals (the recall rate). Applied to real-world patient data from sources including electronic medical records (EMRs) and claims, Proactive Signal Detection technology makes it possible to monitor and assess drug-events efficiently and effectively, without delay and without the need to consult data scientists. This could transform the surveillance of adverse drug reactions, boosting patient safety, while also enabling new benefit-based discoveries to be made - enlarging a drug’s target market. Elizabeth Smalley, Director of Product Management for Data & Analytics at ArisGlobal​, spoke about the importance of proactive signal detection at the recent EU and US World Drug Safety Congress 2023 events. She also cited the study findings in her recent webinar, What Leading Firms Are Prioritizing in Safety Case Reporting and Signal Analytics: ( ). She commented: “Our innovative and proven Proactive Signal Detection technology will revolutionize Pharmacovigilance (PV) with a direct impact on patient safety, as well as a drug’s addressable market. “Signal detection in real-world drug monitoring has hardly changed since the practice was first introduced in response to the thalidomide tragedy of the late 1950s/early 1960s,” she explained. “But now smart analytics, applied to robust real-world data, makes comprehensive, proactive signal detection a reliable reality. The breakthrough could also help identify new opportunities for drug repurposing, so that Safety becomes a driver of commercial benefit as well as a protector of patients.” ArisGlobal’s patent-pending technology, which will be added to ArisGlobal's LifeSphere ecosystem for patient treatment development, performs causal and sensitivity analysis to substantially reduce signal ‘noise’. The technology is another strong addition to the robust and comprehensive LifeSphere ecosystem and a key offering within the company’s data and analytics product line. In a 2022 life sciences industry report from ArisGlobal [1] , 70% of biopharmaceutical professionals indicated a maturity gap in the efficiency of safety signal analytics processing. Outside of the clinical environment, with its inherent limitations, adverse event monitoring relies too heavily on patient and clinician reporting. And, still today, too many adverse events go unreported (up to 95% in the worst cases [2] ). Proactive signal detection, drawing on a broad pool of standardized real-world data, targets this gap. ArisGlobal’s CEO, Mike Gordon, commented, “Proactive signal detection that leverages real-world data will transform patient safety, while overcoming many of the frustrations experienced by drug companies, regulators and clinicians around post-market drug monitoring.” He continues, “We are delighted and proud to lead the market with breakthrough technology that will have a transformative impact on our customers and the industry, and ultimately lead to more safe and effective treatments being put into the hands of clinicians and patients earlier.” About ArisGlobal ArisGlobal is the creator of LifeSphere, a market leader in global patient treatment technology solutions that is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn. . Media Contact [1] What if you could do more with less? Learn how AI and automation can drive business change. Current State of Automation and AI Adoption in Life Sciences: [2] Pharmacovigilance: reporting requirements throughout a product's lifecycle, NIH, September 2022: Editor Details

ArisGlobal Frequently Asked Questions (FAQ)

  • When was ArisGlobal founded?

    ArisGlobal was founded in 1987.

  • Where is ArisGlobal's headquarters?

    ArisGlobal's headquarters is located at 3119 Ponce De Leon Blvd, Miami.

  • What is ArisGlobal's latest funding round?

    ArisGlobal's latest funding round is Acq - Fin - II.

  • Who are the investors of ArisGlobal?

    Investors of ArisGlobal include Nordic Capital, Sapphire Ventures and NetWeaver Fund.

  • Who are ArisGlobal's competitors?

    Competitors of ArisGlobal include Chiral Quest, GI Alliance, Ellkay, Sorcero, 3Analytics and 7 more.


Compare ArisGlobal to Competitors

NCI Cancer Hospital

NCI Cancer Hospital is a private oncology centre in Malaysia that combines treatment and clinical research. NCI aims to provide a range of services from diagnosis, laboratory analysis, surgery, chemotherapy and radiotherapy. It operates to GCP and has conducted clinical trials for a number of pharmaceutical companies including Roche, BMS and AstraZeneca.

Norton Audits Logo
Norton Audits

Norton Audits aims to provide clinical trial monitoring, auditing, and training.

athenahealth Logo

athenahealth focuses on providing cloud-based healthcare products and services, operating in the healthcare technology sector. It offers a range of services including electronic health records, revenue cycle services, patient engagement tools, population health services, telehealth services, and platform services. These services aim to improve clinical efficiency, patient relationships, care coordination, and financial performance in healthcare settings. The company was founded in 1997 and is based in Watertown, Massachusetts.

Chiral Quest

Chiral Quest is a company that specializes in the development and production of intermediates for the pharmaceutical industry. The company's main offerings include the provision of research and production services for intermediates, RSMs, and GMP intermediates, utilizing their unique catalysts and world-class asymmetric hydrogenation technology. Chiral Quest primarily serves the global pharmaceutical industry. It was founded in 2000 and is based in Monmouth Junction, New Jersey.

Pentec Health Logo
Pentec Health

Pentec Health is a healthcare company with a focus on solving and simplifying complex care challenges. The company offers services in renal nutrition, medical foods, and intrathecal services, aimed at improving the health and quality of life for patients with chronic conditions such as chronic kidney disease and end stage renal disease. Pentec Health primarily serves the healthcare industry. It was founded in 1983 and is based in Boothwyn, Pennsylvania.

TriMedx Logo

TriMedx is a clinical asset management company operating in the healthcare sector. The company provides comprehensive clinical engineering services, clinical asset informatics, and medical device cybersecurity, aiming to transform clinical assets into strategic tools for healthcare providers. Its services primarily cater to the healthcare industry. It was founded in 1998 and is based in Indianapolis, Indiana.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.